1. D'Arcy PF. Adverse reactions and interactions with herbal medicines. Part 1. Adverse reactions. Adverse Drug React Toxicol Rev 1991;10:189-208.
2. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250:186-200.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205.
4. Marroum PJ, Uppoor RS, Parmelee T, Ajayi F, Burnett A, Yuan R, Svadjian R, Lesko LJ, Balian JD. In vivo drug-drug interaction studies: a survey of all new molecular entities approved from 1987 to 1997. Clin Pharmacol Ther 2000;68:280-285.
5. Gallicano K, Drusano G. In: Piscitelli SC, Rodvold K, editor. Introduction to drug interactions. Drug interactions in infectious diseases 2005;2nd ed. Totowa: Humana Press Inc. 1-12.
8. Oliver JJ, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010;56:62-67.
9. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-581.
10. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441-457.
11. Omnibus Budget Reconciliation Act of 1990 (OBRA 90), Pub. L. 101-508, 104 Stat. 1388 1990;11. 05.
12. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291.
13. Croxtall JD, Perry CM. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs 2010;70:1885-1915.
14. World Health Organization Expert Committee on the Selection of Essential Drugs. The selection of essential drugs. Report series no. 615 1977;Geneva: World Health Organization.
15. Soumerai SB, Lipton HL. Computer-based drug-utilization review-risk, benefit, or boondoggle? N Engl J Med 1995;332:1641-1645.
16. Park BJ. Drug utilization review. J Pharmacoepidemiol Risk Manag 2008;1:13-19.
17. Park JY. DUR progress in the implementation and ways to expand nationwide. HIRA Policy Trend 2010;4:23-28.
18. Choi NK, Park BJ. Strategy for establishing an effective Korean drug utilization review system. J Korean Med Assoc 2010;53:1130-1138.